A Novel 3D Label-Free Monitoring System of hES-Derived Cardiomyocyte Clusters: A Step Forward to In Vitro Cardiotoxicity Testing

PLoS ONE

Volumn 8, Issue 7, 2013, Pages

  Jahnke, Heinz Georg ^a   Steel, Daniella ^b   Fleischer, Stephan ^a   Seidel, Diana ^a   Kurz, Randy ^a   Vinz, Silvia ^a   Dahlenborg, Kerstin ^b   Sartipy, Peter ^b   Robitzki, Andrea A ^a  

^a Center for Biotechnology and Biomedicine (BBZ)   (Germany)

^b Arvid Wallgrens Backe 20   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

1 [2 (6 METHYL 2 PYRIDYL)ETHYL] 4 (4 METHYLSULFONYLAMINOBENZOYL)PIPERIDINE; DOXORUBICIN; NORADRENALIN;

ACTION POTENTIAL; ARTICLE; CARDIOTOXICITY; CELL ADHESION; CELL GROWTH; DRUG CYTOTOXICITY; ELECTRIC POTENTIAL; ELECTROCHEMICAL IMPEDANCE SPECTROSCOPY; EMBRYONIC STEM CELL; HEART MUSCLE CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; MONITORING; TOXICITY TESTING;

CARDIOTOXINS; CELL AGGREGATION; ELECTROPHYSIOLOGICAL PHENOMENA; EMBRYONIC STEM CELLS; HUMANS; MYOCYTES, CARDIAC; SIGNAL PROCESSING, COMPUTER-ASSISTED; STAINING AND LABELING; TIME FACTORS;

ANIMALIA;

EID: 84879968282     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0068971     Document Type: Article

References (38)

1. Mandenius CF, Steel D, Noor F, Meyer T, Heinzle E, et al. (2011) Cardiotoxicity testing using pluripotent stem cell-derived human cardiomyocytes and state-of-the-art bioanalytics: a review. J Appl Toxicol 31: 191-205.
2. Jonsson MK, Vos MA, Mirams GR, Duker G, Sartipy P,et al. (2012) Application of human stem cell-derived cardiomyocytes in safety pharmacology requires caution beyond hERG. J Mol Cell Cardiol.
3. Sheppard RJ, Berger J, Sebag IA, (2013) Cardiotoxicity of cancer therapeutics: current issues in screening, prevention, and therapy. Front Pharmacol 4: 19.
4. Lu HR, Marien R, Saels A, De Clerck F, (2001) Species plays an important role in drug-induced prolongation of action potential duration and early afterdepolarizations in isolated Purkinje fibers. J Cardiovasc Electrophysiol 12: 93-102.
5. Asp J, Steel D, Jonsson M, Ameen C, Dahlenborg K, et al. (2010) Cardiomyocyte clusters derived from human embryonic stem cells share similarities with human heart tissue. J Mol Cell Biol 2: 276-283.
6. Ye L, Zhang S, Greder L, Dutton J, Keirstead SA, et al. (2013) Effective cardiac myocyte differentiation of human induced pluripotent stem cells requires VEGF. PLoS One 8: e53764.
7. Burridge PW, Thompson S, Millrod MA, Weinberg S, Yuan X, et al. (2011) A universal system for highly efficient cardiac differentiation of human induced pluripotent stem cells that eliminates interline variability. PLoS One 6: e18293.
8. Synnergren J, Akesson K, Dahlenborg K, Vidarsson H, Ameen C, et al. (2008) Molecular signature of cardiomyocyte clusters derived from human embryonic stem cells. Stem Cells 26: 1831-1840.
9. Synnergren J, Ameen C, Jansson A, Sartipy P, (2012) Global transcriptional profiling reveals similarities and differences between human stem cell-derived cardiomyocyte clusters and heart tissue. Physiol Genomics 44: 245-258.
10. Steel D, Hyllner J, Sartipy P, (2009) Cardiomyocytes derived from human embryonic stem cells- characteristics and utility for drug discovery. Curr Opin Drug Discov Devel 12: 133-140.
11. Zhu WZ, Santana LF, Laflamme MA, (2009) Local control of excitation-contraction coupling in human embryonic stem cell-derived cardiomyocytes. PLoS One 4: e5407.
12. Vidarsson H, Hyllner J, Sartipy P, (2010) Differentiation of human embryonic stem cells to cardiomyocytes for in vitro and in vivo applications. Stem Cell Rev 6: 108-120.
13. Nalos L, Varkevisser R, Jonsson MK, Houtman MJ, Beekman JD, et al. (2012) Comparison of the IKr blockers moxifloxacin, dofetilide and E-4031 in five screening models of pro-arrhythmia reveals lack of specificity of isolated cardiomyocytes. Br J Pharmacol 165: 467-478.
14. Otsuji TG, Minami I, Kurose Y, Yamauchi K, Tada M, et al. (2010) Progressive maturation in contracting cardiomyocytes derived from human embryonic stem cells: Qualitative effects on electrophysiological responses to drugs. Stem Cell Res 4: 201-213.
15. Rothermel A, Kurz R, Ruffer M, Weigel W, Jahnke HG, et al. (2005) Cells on a chip-the use of electric properties for highly sensitive monitoring of blood-derived factors involved in angiotensin II type 1 receptor signalling. Cell Physiol Biochem 16: 51-58.
16. Braam SR, Tertoolen L, van de Stolpe A, Meyer T, Passier R, et al. (2010) Prediction of drug-induced cardiotoxicity using human embryonic stem cell-derived cardiomyocytes. Stem Cell Res 4: 107-116.
17. Reppel M, Igelmund P, Egert U, Juchelka F, Hescheler J, et al. (2007) Effect of cardioactive drugs on action potential generation and propagation in embryonic stem cell-derived cardiomyocytes. Cell Physiol Biochem 19: 213-224.
18. Kloss D, Kurz R, Jahnke HG, Fischer M, Rothermel A, et al. (2008) Microcavity array (MCA)-based biosensor chip for functional drug screening of 3D tissue models. Biosens Bioelectron 23: 1473-1480.
19. Krinke D, Jahnke HG, Panke O, Robitzki AA, (2009) A microelectrode-based sensor for label-free in vitro detection of ischemic effects on cardiomyocytes. Biosens Bioelectron 24: 2798-2803.
20. Haas S, Jahnke HG, Glass M, Azendorf R, Schmidt S, et al. (2010) Real-time monitoring of relaxation and contractility of smooth muscle cells on a novel biohybrid chip. Lab Chip 10: 2965-2971.
21. Krinke D, Jahnke HG, Mack TG, Hirche A, Striggow F, et al. (2010) A novel organotypic tauopathy model on a new microcavity chip for bioelectronic label-free and real time monitoring. Biosens Bioelectron 26: 162-168.
22. Jahnke HG, Braesigk A, Mack TG, Ponick S, Striggow F, et al. (2012) Impedance spectroscopy based measurement system for quantitative and label-free real-time monitoring of tauopathy in hippocampal slice cultures. Biosens Bioelectron 32: 250-258.
23. Omata T, Kasai C, Hashimoto M, Hombo T, Yamamoto K, (2005) QT PRODACT: comparison of non-clinical studies for drug-induced delay in ventricular repolarization and their role in safety evaluation in humans. J Pharmacol Sci 99: 531-541.
24. Kloss D, Fischer M, Rothermel A, Simon JC, Robitzki AA, (2008) Drug testing on 3D in vitro tissues trapped on a microcavity chip. Lab Chip 8: 879-884.
25. Jahnke HG, Rothermel A, Sternberger I, Mack TG, Kurz RG, et al. (2009) An impedimetric microelectrode-based array sensor for label-free detection of tau hyperphosphorylation in human cells. Lab Chip 9: 1422-1428.
26. Berridge BR, Pettit S, Walker DB, Jaffe AS, Schultze AE, et al. (2009) A translational approach to detecting drug-induced cardiac injury with cardiac troponins: consensus and recommendations from the Cardiac Troponins Biomarker Working Group of the Health and Environmental Sciences Institute. Am Heart J 158: 21-29.
27. Lee P, Klos M, Bollensdorff C, Hou L, Ewart P, et al. (2012) Simultaneous voltage and calcium mapping of genetically purified human induced pluripotent stem cell-derived cardiac myocyte monolayers. Circ Res 110: 1556-1563.
28. Kamakura T, Makiyama T, Sasaki K, Yoshida Y, Wuriyanghai Y, et al. (2013) Ultrastructural maturation of human-induced pluripotent stem cell-derived cardiomyocytes in a long-term culture. Circ J 77: 1307-1314.
29. Zhang J, Klos M, Wilson GF, Herman AM, Lian X, et al. (2012) Extracellular matrix promotes highly efficient cardiac differentiation of human pluripotent stem cells: the matrix sandwich method. Circ Res 111: 1125-1136.
30. Halbach M, Egert U, Hescheler J, Banach K, (2003) Estimation of action potential changes from field potential recordings in multicellular mouse cardiac myocyte cultures. Cell Physiol Biochem 13: 271-284.
31. Ungrin MD, Joshi C, Nica A, Bauwens C, Zandstra PW, (2008) Reproducible, ultra high-throughput formation of multicellular organization from single cell suspension-derived human embryonic stem cell aggregates. PLoS One 3: e1565.
32. Narsinh K, Narsinh KH, Wu JC, (2011) Derivation of human induced pluripotent stem cells for cardiovascular disease modeling. Circ Res 108: 1146-1156.
33. Bohm M, La Rosee K, Schwinger RH, Erdmann E, (1995) Evidence for reduction of norepinephrine uptake sites in the failing human heart. J Am Coll Cardiol 25: 146-153.
34. Redfern WS, Carlsson L, Davis AS, Lynch WG, MacKenzie I, et al. (2003) Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovasc Res 58: 32-45.
35. Guglin M, Aljayeh M, Saiyad S, Ali R, Curtis AB, (2009) Introducing a new entity: chemotherapy-induced arrhythmia. Europace 11: 1579-1586.
36. Pointon A, Abi-Gerges N, Cross MJ, Sidaway JE (2013) Phenotypic Profiling of Structural Cardiotoxins In Vitro Reveals Dependency on Multiple Mechanisms of Toxicity. Toxicol Sci.
37. Andersson H, Steel D, Asp J, Dahlenborg K, Jonsson M, et al. (2010) Assaying cardiac biomarkers for toxicity testing using biosensing and cardiomyocytes derived from human embryonic stem cells. J Biotechnol 150: 175-181.
38. Eckes J, Schmah O, Siebers JW, Groh U, Zschiedrich S, et al. (2011) Kinetic targeting of pegylated liposomal doxorubicin: a new approach to reduce toxicity during chemotherapy (CARL-trial). BMC Cancer 11: 337.